Zhang et al., 2021 - Google Patents
ATF3 drives senescence by reconstructing accessible chromatin profilesZhang et al., 2021
View PDF- Document ID
- 9257268116234585200
- Author
- Zhang C
- Zhang X
- Huang L
- Guan Y
- Huang X
- Tian X
- Zhang L
- Tao W
- Publication year
- Publication venue
- Aging Cell
External Links
Snippet
Chromatin organization and transcriptional profiles undergo tremendous reordering during senescence. However, uncovering the regulatory mechanisms between chromatin reconstruction and gene expression in senescence has been elusive. Here, we depicted the …
- 230000032683 aging 0 title abstract description 179
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1079—Screening libraries by altering the phenotype or phenotypic trait of the host
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6802—General aspects
- C12Q1/6809—Sequence identification involving differential detection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Zhang et al. | ATF3 drives senescence by reconstructing accessible chromatin profiles | |
| Funato et al. | Dissecting the impact of regional identity and the oncogenic role of human-specific NOTCH2NL in an hESC model of H3. 3G34R-mutant glioma | |
| Collin et al. | Transcriptional repression of DNA repair genes is a hallmark and a cause of cellular senescence | |
| Miller et al. | Transcription elongation factors represent in vivo cancer dependencies in glioblastoma | |
| Zhou et al. | BCLAF1 and its splicing regulator SRSF10 regulate the tumorigenic potential of colon cancer cells | |
| Schwoerer et al. | Epigenetic stress responses induce muscle stem-cell ageing by Hoxa9 developmental signals | |
| Spruijt et al. | ZMYND8 co-localizes with NuRD on target genes and regulates poly (ADP-ribose)-dependent recruitment of GATAD2A/NuRD to sites of DNA damage | |
| Miller et al. | TOP2 synergizes with BAF chromatin remodeling for both resolution and formation of facultative heterochromatin | |
| Jing et al. | Genome-wide CRISPR activation screening in senescent cells reveals SOX5 as a driver and therapeutic target of rejuvenation | |
| Bonfanti et al. | PW1/Peg3 expression regulates key properties that determine mesoangioblast stem cell competence | |
| Siaw et al. | 11q deletion or ALK activity curbs DLG2 expression to maintain an undifferentiated state in neuroblastoma | |
| Sheppard et al. | Targeted brachyury degradation disrupts a highly specific autoregulatory program controlling chordoma cell identity | |
| Lee et al. | Cockayne syndrome group B deficiency reduces H3K9me3 chromatin remodeler SETDB1 and exacerbates cellular aging | |
| Wang et al. | Unveiling E2F4, TEAD1 and AP-1 as regulatory transcription factors of the replicative senescence program by multi-omics analysis | |
| Dedeic et al. | Emerin inhibits Lmo7 binding to the Pax3 and MyoD promoters and expression of myoblast proliferation genes | |
| Chu et al. | Unique immune cell coactivators specify locus control region function and cell stage | |
| Singh et al. | Analysis of the SWI/SNF chromatin-remodeling complex during early heart development and BAF250a repression cardiac gene transcription during P19 cell differentiation | |
| Sinha et al. | Pbrm1 steers mesenchymal stromal cell osteolineage differentiation by integrating PBAF-dependent chromatin remodeling and BMP/TGF-β signaling | |
| Tomimatsu et al. | Locus-specific induction of gene expression from heterochromatin loci during cellular senescence | |
| Baumgart et al. | CHD1 regulates cell fate determination by activation of differentiation-induced genes | |
| Silva et al. | Ribosome impairment regulates intestinal stem cell identity via ZAKɑ activation | |
| Beermann et al. | A large shRNA library approach identifies lncRNA Ntep as an essential regulator of cell proliferation | |
| Kanki et al. | Bivalent-histone-marked immediate-early gene regulation is vital for VEGF-responsive angiogenesis | |
| Schmolka et al. | Dissecting the roles of MBD2 isoforms and domains in regulating NuRD complex function during cellular differentiation | |
| Miller et al. | p53 enhances DNA repair and suppresses cytoplasmic chromatin fragments and inflammation in senescent cells |